Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Abstract The PASADENA study is an ongoing Phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of intravenous prasinezumab, administered every 4 weeks, in early-stage Parkinson’s disease (PD). During the double-blind study period, prasinezumab-treated individuals showed less progression of motor signs (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III). We evaluated here whether the effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part II scores was sustained over 4 years from the start of the trial. We compared participants enrolled in the PASADENA open-label extension (OLE) to an external comparator arm derived from the Parkinson's Progression Markers Initiative (PPMI) observational study. Both PASADENA delayed- (n = 94) and early-start (n = 177) groups showed a slower decline (less increase in score) on MDS-UPDRS Part III in OFF- (-51% for the delayed-start group and − 65% for the early-start group) and ON-state (-94% for the delayed-start group and − 118% for the early-start group), and on MDS-UPDRS Part II (-48% for the delayed-start group and − 40% for the early-start group), compared with the PPMI external comparator (n = 303). This exploratory analysis, which requires confirmation in future studies, suggests that the effect of prasinezumab in slowing motor progression in PD may be sustained long-term..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 08. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pagano, Gennaro [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-4232431/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA043206972 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA043206972 | ||
| 003 | DE-627 | ||
| 005 | 20240409131104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-4232431/v1 |2 doi | |
| 035 | |a (DE-627)XRA043206972 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-4232431/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pagano, Gennaro |e verfasserin |0 (orcid)0000-0002-6247-8988 |4 aut | |
| 245 | 1 | 0 | |a Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The PASADENA study is an ongoing Phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of intravenous prasinezumab, administered every 4 weeks, in early-stage Parkinson’s disease (PD). During the double-blind study period, prasinezumab-treated individuals showed less progression of motor signs (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III). We evaluated here whether the effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part II scores was sustained over 4 years from the start of the trial. We compared participants enrolled in the PASADENA open-label extension (OLE) to an external comparator arm derived from the Parkinson's Progression Markers Initiative (PPMI) observational study. Both PASADENA delayed- (n = 94) and early-start (n = 177) groups showed a slower decline (less increase in score) on MDS-UPDRS Part III in OFF- (-51% for the delayed-start group and − 65% for the early-start group) and ON-state (-94% for the delayed-start group and − 118% for the early-start group), and on MDS-UPDRS Part II (-48% for the delayed-start group and − 40% for the early-start group), compared with the PPMI external comparator (n = 303). This exploratory analysis, which requires confirmation in future studies, suggests that the effect of prasinezumab in slowing motor progression in PD may be sustained long-term. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Monnet, Annabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Ribba, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Svoboda, Hanno |e verfasserin |4 aut | |
| 700 | 1 | |a Kustermann, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Simuni, Tanya |e verfasserin |4 aut | |
| 700 | 1 | |a Postuma, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Pavese, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Stocchi, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Brockmann, Kathrin |e verfasserin |0 (orcid)0000-0002-7515-8596 |4 aut | |
| 700 | 1 | |a Smigorski, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Gerbaldo, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Fontoura, Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Doody, Rachelle |e verfasserin |4 aut | |
| 700 | 1 | |a Kerchner, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Brundin, Patrik |e verfasserin |4 aut | |
| 700 | 1 | |a Marek, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Bonni, Azad |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolcheva, Tania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 08. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-4232431/v1 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 04 | ||